Building on synthetic immunology and T cell engineering: a brief journey through the history of CARs.
出版年份 2021 全文链接
标题
Building on synthetic immunology and T cell engineering: a brief journey through the history of CARs.
作者
关键词
-
出版物
HUMAN GENE THERAPY
Volume -, Issue -, Pages -
出版商
Mary Ann Liebert Inc
发表日期
2021-08-18
DOI
10.1089/hum.2021.165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells
- (2021) Mario Bunse et al. Nature Communications
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML
- (2021) Martin Wermke et al. BLOOD
- A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
- (2021) Matthias Bozza et al. Science Advances
- How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy
- (2021) Christopher E. Rudd Frontiers in Cell and Developmental Biology
- Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors
- (2021) Emre Balta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Chemically Programmable and Switchable CAR‐T Therapy
- (2020) Junpeng Qi et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
- (2020) Theodore L. Roth et al. CELL
- The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
- (2020) Marco Cerrano et al. Frontiers in Immunology
- Senolytic CAR T cells reverse senescence-associated pathologies
- (2020) Corina Amor et al. NATURE
- Clinical development of CAR T cell therapy in China: 2020 update
- (2020) Jianshu Wei et al. Cellular & Molecular Immunology
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
- (2019) Matthew R. Collinson-Pautz et al. LEUKEMIA
- Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
- (2019) Shivani Srivastava et al. CANCER CELL
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
- (2019) Michael Bachmann IMMUNOLOGY LETTERS
- Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
- (2019) Eytan Herzig et al. CELL
- Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- CD28-ζ CAR T cells resist TGF-β repression through IL-2 signaling which can be mimicked by IL-7 and an engineered IL-7/IL-2Rβ autocrine loop
- (2018) Viktória Golumba-Nagy et al. MOLECULAR THERAPY
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
- (2018) Eric L. Smith et al. MOLECULAR THERAPY
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
- (2018) Deepak Raj et al. GUT
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
- (2018) Najat Bouchkouj et al. CLINICAL CANCER RESEARCH
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells
- (2017) Hinrich Abken HUMAN GENE THERAPY
- Fully human CD19-specific chimeric antigen receptors for T-cell therapy
- (2017) D Sommermeyer et al. LEUKEMIA
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity
- (2017) Patrick Ho et al. ACS Synthetic Biology
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
- (2017) A. Kunert et al. OncoImmunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
- (2016) Leonardo Morsut et al. CELL
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- (2016) David T. Rodgers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
- (2016) Fengtao You et al. Science China-Life Sciences
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
- (2015) L. Zhang et al. CLINICAL CANCER RESEARCH
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFN
- (2014) A. Textor et al. CANCER RESEARCH
- Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer
- (2014) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
- (2014) Ann M Leen et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
- (2013) Markus Chmielewski et al. IMMUNOLOGICAL REVIEWS
- Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”
- (2013) Andreas A Hombach et al. MOLECULAR THERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models
- (2012) J. H. Shin et al. BLOOD
- A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
- (2012) K. Urbanska et al. CANCER RESEARCH
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
- (2012) J. Scholler et al. Science Translational Medicine
- Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling
- (2011) Andreas A. Hombach et al. INTERNATIONAL JOURNAL OF CANCER
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
- (2010) J. M. Seeger et al. CANCER RESEARCH
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
- (2010) Scott Wilkie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The TCR-mediated signaling pathways that control the direction of helper T cell differentiation
- (2010) Toshinori Nakayama et al. SEMINARS IN IMMUNOLOGY
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rational development of high-affinity T-cell receptor-like antibodies
- (2009) G. Stewart-Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search